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Background: Prior to initiating immunosuppressive therapy in the treatment of autoimmune inflammatory
conditions, it is a requirement to screen for certain viral serology, including hepatitis B (HBV). A positive result may
indicate the need for antiviral therapy, or contraindicate immunosuppression all together. An accurate
interpretation of serological markers is therefore imperative in order to treat patients appropriately. We present
a case of passive anti-HBV antibody transfer following intravenous immunoglobulin (IVIg) infusion, in which
misinterpretation of serology results almost led to inappropriate treatment with antiviral therapy and the withholding
of immunosuppressive agents. This phenomenon has been previously reported, but awareness remains limited.
Case presentation: A 50 year old Caucasian gentleman with a history of allogeneic haematopoietic stem cell
transplant for transformed follicular lymphoma was admitted to hospital with recurrent respiratory tract infections.
Investigation found him to be hypogammaglobulinaemic, and he was thus given 1 g/kg of intravenous
immunoglobulin. The patient also disclosed a 3-week history of painful, swollen joints, leading to a diagnosis of
seronegative inflammatory polyarthritis. Prior to initiating long term immunosuppression, viral screening found hepatitis
B serology suggestive of past infection, with positive results for both anti-HBc and anti-HBs antibody, but negative HBV
DNA. In response, prednisolone was weaned and the local hepatology team recommended commencement of
lamivudine. Having been unable to identify a source of infection, the case was reported to the local blood centre,
who tested a remaining vial from the same batch of IVIg and found it to be anti-HBc and anti-HBs positive. Fortunately
the blood products were identified and tested prior to the patient initiating HBV treatment, and the effect of a delay in
starting disease-modifying therapy was inconsequential in light of an excellent response to first-line therapies.
Conclusion: Misinterpretation of serology results following IVIg infusion may lead to significant patient harm,
including unnecessary antiviral administration, the withholding of treatments, and psychosocial damage. This is
especially pertinent at a time when we have an ever increasing number of patients being treated with IVIg for a wide
array of immune-mediated disease. Passive antibody transfer should be considered wherever unexpected serological
changes are identified.
Keywords: Hepatitis B virus, Intravenous immunoglobulin, Passive antibody transfer, Seronegative inflammatory
polyarthritis, Lymphoma, Haematopoietic stem cell transplant, ImmunosuppressionBackground
Reactivation of hepatitis B virus (HBV) is a recognised
complication of immunosuppressive therapy, potentially
resulting in hepatocellular injury, liver failure and death
[1]. As such, the European Association for the Study of
the Liver (EASL) recommend that all patients receiving
cytotoxic or immunosuppressive therapy are screened
for serological markers of HBV infection (HBsAg, anti-* Correspondence: simonjmparker@gmail.com
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unless otherwise stated.HBc, and anti-HBs) (Table 1) [2]. The majority of cases of
reactivation occur in patients with chronic (HBsAg posi-
tive, HBV DNA >2000 IU/ml) or inactive (HBsAg positive,
HBV DNA <2000 IU/ml) HBV infection. In these instan-
ces prophylactic antiviral therapy is advised [3,4]. There
are also increasing numbers of cases of HBV reactivation
among patients with occult HBV infection, where HBsAg
is negative and anti-HBc positive, particularly where im-
munosuppression is with rituximab [5,6]. The manage-
ment of these patients remains controversial [7]. The lacktd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Hepatitis B serology profiles
Status HBsAg HBsAb HBcAB IgM HBcAB IgG HBeAg HBeAb HBV-DNA
Acute infection + − + − + − +
Resolved acute infection − + − + − + −
Chronic carrier + − − +/− − + −
Chronic active infection + − − +/− + − +
Vaccinated − + − − − − −
Passive Ab transfer − +/− +/− +/− − +/− −
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cautious approach may be advisable [2].
Given the clinical implications, the correct interpret-
ation of hepatitis B viral serology in the context of im-
munosuppression is of great importance. We describe a
case of passive anti-HBV antibody transfer from an in-
travenous immunoglobulin infusion which almost resu-
lted in unnecessary treatment for HBV infection, and
urge clinicians to consider passive antibody transfer as a
cause of positive viral serology.
Case report
A 50 year old gentleman with a history of allogeneic
haemopoietic stem cell transplant for transformed fol-
licular lymphoma was admitted to hospital in July 2012
with pneumonia. He had undergone reduced intensity
transplant in January 2008, with modest red cell and
platelet support, and had a biopsy-proven high grade re-
lapse in March 2009, treated with rituximab followed by
a donor lymphocyte infusion. He had been in metabo-
lic complete remission since then, and had been well,
though with occasional respiratory tract infections. In
early 2012 these became more frequent. He was found
to be hypogammaglobulinemic, presumed to be secondary
to rituximab, and was given 1 g/kg of intravenous im-
munoglobulin (Vigam®).
The patient also disclosed a 3 week history of painful,
swollen joints, as well as morning stiffness of 5-6 hours
for the several months, primarily affecting the small
joints of the hands, right knee and both ankles. He was
diagnosed with a seronegative inflammatory polyarthri-
tis, and initially treated in hospital with steroid injection
to the right knee, a short course of oral prednisilone andFigure 1 Timeline of events and serology results. *No absolute titre procommencement of hydroxychloroquine. He responded
well, and following discharge the decision was made to
continue long term hydroxychloroquine and to initiate
sulfasalazine. Prior to the initiation of this immuno-
suppressive therapy, routine viral serology was reques-
ted including hepatitis B, hepatitis C and HIV. The
hepatitis B serology was reported as indicative of past
infection, with positive results for both anti-HBc and
anti-HBs antibody, but no detectable HBsAg or HBV
DNA (Figure 1). His ALT, bilirubin and albumin were
in the normal range (22 iU/ml, 6 mcmol/ml and 42 g/L
respectively), and his alkaline phosphatase was slightly
elevated at 143 IU/L (normal range 40-129 IU/L), but nor-
malized with control of his arthritis and was 107 IU/L the
following month.
The abnormal hepatitis B serology was unexpected, as
prior to transplant, serology and HBV DNA testing of
both donor and recipient were negative, and his sibling
donor underwent repeat negative testing when donor
lymphocytes were harvested post-transplant. In addition,
he had been intensively followed up during the period
of profound immunosuppression post-transplant and
then the phase of immune reconstitution, with no cli-
nical evidence of a hepatitic illness and normal liver
function tests.
In response to these results his prednisolone was
weaned and a referral made to the local hepatology team,
who recommended commencement of lamivudine, to be
continued for the duration of his immunosuppressive
therapy.
Discussion of our findings with the patient failed to
indicate a probable source of the infection. He denied
any illicit drug use or unsafe sexual practice, and thevided.
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siderable marital discord. It was also curious that an
immunosuppressed patient could contract acute HBV
without clinical signs or symptoms, any derangement
to his liver function tests, and without the development of
a chronic infection.
The case was reported to the local blood centre for
consideration of investigation of the 2008 blood compo-
nents as the source of the HBV infection. At that time,
the possibility of the positive HBV markers resulting
from the IVIg treatment he received for hypogamma-
globulinaemia a few weeks previously was also raised.
The patient had received 10 × 10 g vials of Vigam® IVIg
(manufacturer: BPL; BioProducts Laboratory ltd) and
batch details had been recorded in medical records. A
vial remaining from the same batch was tested and
found to be both anti-HBc and anti-HBs positive, sug-
gesting the patient could have been the passive recipi-
ent of anti-HBc and anti-HBs antibody. This suggestion
was supported by ongoing blood monitoring which de-
monstrated a fall in anti-HBs titre, from 748 mIU/ml
initially, to 359 mlU/ml 3 weeks later.
Fortunately the blood products were identified and
tested prior to the patient initiating HBV treatment with
lamivudine, and the effect of a delay in starting DMARD
therapy was inconsequential in light of an excellent re-
sponse to first-line therapies.Discussion and conclusions
IVIg is a plasma-derived product consisting of concen-
trated immunoglobulin, predominantly IgG. It was first
introduced for the treatment of primary humoral im-
munodeficiencies, but has since been used in the treat-
ment of a variety of immune-mediated diseases, such as
acquired hypogammaglobulinemia, idiopathic thrombo-
cytopenia and HIV-associated thrombocytopenia, for ex-
ample [8]. The passive transfer of antibody from IVIg
has previously been reported, [9-11] but there remains
limited awareness of this, and passive antibody transfer
is not routinely considered in the interpretation of a re-
cipients viral serology results. This may be in part due to
the assumption that all blood products are screened for
viral antibody and discarded if positive. It is true that
this process does occur in some blood services, but this
does not necessarily apply to all plasma suppliers, even
within the same country. More commonly, donors are
screened for HBsAg and HBV DNA only, allowing con-
tributions from non-infectious patients with positive HBV
serology to be used [12]. Vigam® is produced by BPL, a
UK company, but manufactured from non-UK plasma.
The fact that the final product contained anti-HBc dem-
onstrates that the starting plasma was not screened for
anti-HBc.A 2010 Canadian case-control study looked retros-
pectively for an association between anti-HBc seroposi-
tivity and past exposure to IVIg, and found an odds ratio
of 16 for anti-HBc positive participants having had past
IVIg infusions (95% confidence interval, 1.5-166.1). Fur-
thermore, samples of IVIG from 3 of 5 different blood
product manufacturers tested positive for anti-HBc [13].
The manufacturer’s Summary of Product Characteristics
(SPC) for the product used in this case clearly states
that: “Vigam® Liquid contains mainly immunoglobulin G
(IgG), and has a broad spectrum of antibodies against
various infectious agents. Vigam® Liquid contains the IgG
antibodies present in the normal population and is pre-
pared from pooled plasma from not fewer than 1000
donors”. IVIg has a 21- to 24-day half-life, meaning that
antibodies passively acquired will be cleared within 3-4
months of the final dose, [11] and this case clearly demon-
strates the falling antibody titres seen in passive antibody
transfer.
The risk of infectious complications from IVIg is
extremely low, with stringent donor screening require-
ments meaning there have been no reported cases of HBV
or HIV transmission [8]. The importance of passive trans-
fer of antibodies as a common consequence of the admin-
istration of IVIg relates to the risk of misinterpretation of
serology results, and hence mismanagement of patients,
rather than an infection risk. This risk is also present with
other immunoglobulin-based products, such as subcuta-
neous immunoglobulin (SCIg) or specific Ig preparations,
which contain high concentrations of antibody to a spe-
cific pathogen (in such instances the risk may be re-
duced, however, due to the relative reduction of other
antibodies). An incorrect diagnosis of occult HBV in-
fection may not only lead to the unnecessary prescrip-
tion of potentially harmful antiviral agents but also the
patient being denied beneficial treatments. In this case,
the patient was advised to start lamivudine, a nucleoside
analogue most suitable for the treatment of those with
low (<2000 IU/ml) HBV DNA levels [2]. Although having
a relatively benign toxicity profile, known potential side ef-
fects of lamivudine include elevations in amylase, lipase
and creatine kinase, nausea, headache, dizziness, and pan-
creatitis [14]. There is also the potential for significant
psychosocial harm as a result of an incorrect diagnosis.
Chronic HBV infection and carrier states can have a sig-
nificant negative impact on health-related quality of life,
resulting in significant psychiatric morbidity (predomi-
nantly depression) [15,16].
With an ever increasing number of patients being treated
with IVIg for a wide array of immune-mediated disease, it
is important that passive antibody transfer is considered
when unexpected serological changes are identified. Our
case helps to demonstrate some of the clues that may lead
the clinician to recognise a false-positive result:
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of source, symptoms or signs.
2) Recent transfusion of immunoglobulin-containing
products.
3) The presence of antibodies without viral antigen
or DNA.
4) The presence of IgG anti-HBcAb but lack of IgM
anti-HBcAb antibody (in our case, we tested for
IgG only. Given the predominance of IgG in IVIg
products, it would have been prudent to check
IgM levels as well, as the likely negative result
would have further pointed towards a false-
positive conclusion).
5) Falling antibody titres over the following weeks.
Increased awareness and active consideration of the pas-
sive transfer of clinically significant antibodies from im-
munoglobulin treatments will help prevent unnecessary
anxiety, antiviral therapy and the withholding of essential
immunosuppressive agents. Patients should be informed,
appropriately counselled and reassured as to the effect
that this treatment may have on subsequent blood tests,
and where possible, pre-treatment serological screen-
ing of both the patient and the blood product should
be considered.
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